AMCP: Don't require Part D plans to include all drugs for serious conditions
AMCP has sent a letter to Senate leaders strongly objecting to Section 176 of S. 3101.
The Academy of Managed Care Pharmacy (AMCP) has sent a letter to key Democrat and Republican Senate leaders strongly objecting to Section 176 of S. 3101, the "Medicare Improvements for Patients and Providers Act of 2008." The provision would require the Department of Health & Human Services to identify classes of drugs used to treat major or life-threatening conditions and require formularies of Medicare Part D drug plan sponsors to include "all or substantially all" of the drugs in that class. AMCP believes this provision would undermine the current process mandated by the Medicare Modernization Act by which drugs are evaluated for clinical effectiveness and safety. AMCP also believes this provision is unnecessary and inconsistent with the competitive structure that forms the foundation of the Part D benefit.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
